Colin Collins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11084796/publications.pdf

Version: 2024-02-01

64 9,073 38 62
papers citations h-index g-index

65 65 65 10857 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nature Genetics, 1998, 20, 207-211.	21.4	2,066
2	PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genetics, 1999, 21, 99-102.	21.4	1,041
3	Chromosome aberrations in solid tumors. Nature Genetics, 2003, 34, 369-376.	21.4	702
4	Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nature Genetics, 2000, 25, 144-146.	21.4	555
5	TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion. American Journal of Surgical Pathology, 2007, 31, 882-888.	3.7	394
6	Widespread and Functional RNA Circularization in Localized Prostate Cancer. Cell, 2019, 176, 831-843.e22.	28.9	317
7	Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nature Genetics, 2001, 29, 459-464.	21.4	268
8	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncology, 2015, 1, 466.	7.1	264
9	Zf9, a Kruppel-like transcription factor up-regulatedin vivoduring early hepatic fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9500-9505.	7.1	234
10	Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nature Genetics, 2002, 31, 301-305.	21.4	220
11	Genome changes and gene expression in human solid tumors. Carcinogenesis, 2000, 21, 443-452.	2.8	174
12	Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Human Molecular Genetics, 2004, 13, 1303-1313.	2.9	171
13	ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene, 1997, 14, 1617-1622.	5.9	159
14	Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Molecular Cancer Therapeutics, 2006, 5, 853-867.	4.1	157
15	Overexpression, Amplification, and Androgen Regulation of TPD52 in Prostate Cancer. Cancer Research, 2004, 64, 3814-3822.	0.9	145
16	SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. European Urology, 2017, 71, 68-78.	1.9	136
17	REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Research, 2014, 42, 999-1015.	14.5	125
18	End-sequence profiling: Sequence-based analysis of aberrant genomes. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 7696-7701.	7.1	119

#	Article	IF	CITATIONS
19	Genome Amplification of Chromosome 20 in Breast Cancer. Breast Cancer Research and Treatment, 2003, 78, 337-345.	2.5	100
20	The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer. Epigenomics, 2016, 8, 721-731.	2.1	94
21	Highâ€resolution array comparative genomic hybridization of chromosome arm 8q: Evaluation of genetic progression markers for prostate cancer. Genes Chromosomes and Cancer, 2005, 44, 438-449.	2.8	85
22	Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer, 2012, 12, 78.	2.6	85
23	Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23–qter and identifies underlying candidate tumor suppressor genes in prostate cancer. Oncogene, 2004, 23, 3487-3494.	5.9	78
24	Identification of Ovarian Cancer Metastatic miRNAs. PLoS ONE, 2013, 8, e58226.	2.5	78
25	High-Resolution Analysis of Paraffin-Embedded and Formalin-Fixed Prostate Tumors Using Comparative Genomic Hybridization to Genomic Microarrays. American Journal of Pathology, 2003, 162, 763-770.	3.8	76
26	Evaluation of Paired-End Sequencing Strategies for Detection of Genome Rearrangements in Cancer. PLoS Computational Biology, 2008, 4, e1000051.	3.2	72
27	The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo. Molecular Cancer, 2015, 14, 46.	19.2	71
28	nFuse: Discovery of complex genomic rearrangements in cancer using high-throughput sequencing. Genome Research, 2012, 22, 2250-2261.	5.5	67
29	Expression Profiling of Primary and Metastatic Ovarian Tumors Reveals Differences Indicative of Aggressive Disease. PLoS ONE, 2014, 9, e94476.	2.5	66
30	ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. Human Molecular Genetics, 2005, 14, 3219-3225.	2.9	60
31	Reconstructing tumor genome architectures. Bioinformatics, 2003, 19, ii162-ii171.	4.1	58
32	Genomic organization and complete sequence of the human gene encoding the \hat{l}^2 -subunit of the cGMP phosphodiesterase and its localisation to 4p16.3. Nucleic Acids Research, 1991, 19, 6263-6268.	14.5	57
33	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nature Communications, 2021, 12, 7349.	12.8	51
34	A physical map of chromosome 20 established using fluorescence in situ hybridization and digital image analysis. Genomics, 1995, 26, 134-137.	2.9	50
35	Decoding the fine-scale structure of a breast cancer genome and transcriptome. Genome Research, 2006, 16, 394-404.	5.5	49
36	Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. Oncotarget, 2017, 8, 18949-18967.	1.8	47

#	Article	IF	CITATIONS
37	Evaluation of genetic patterns in different tumor areas of intermediateâ€grade prostatic adenocarcinomas by highâ€resolution genomic array analysis. Genes Chromosomes and Cancer, 2004, 39, 249-256.	2.8	46
38	ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells. Molecular Cancer, 2010, 9, 291.	19.2	42
39	Comrad: detection of expressed rearrangements by integrated analysis of RNA-Seq and low coverage genome sequence data. Bioinformatics, 2011, 27, 1481-1488.	4.1	39
40	miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer. Scientific Reports, 2017, 7, 4079.	3.3	37
41	The human \hat{I}^2 -subunit of rod photoreceptor cGMP phosphodiesterase: Complete retinal cDNA sequence and evidence for expression in brain. Genomics, 1992, 13, 698-704.	2.9	35
42	A Group of Genome-Based Biomarkers That Add to a Kattan Nomogram for Predicting Progression in Men with High-Risk Prostate Cancer. Clinical Cancer Research, 2010, 16, 195-202.	7.0	34
43	Genomic Organization, Sequence, and Chromosomal Localization of the Human Helix–Loop–Helix Id1 Gene. Biochemical and Biophysical Research Communications, 1997, 231, 628-634.	2.1	33
44	Characterization of the novel amplified in breast cancer-1 (NABC1) gene product. Experimental Cell Research, 2003, 290, 402-413.	2.6	28
45	Comprehensive Genome Sequence Analysis of a Breast Cancer Amplicon. Genome Research, 2001, 11, 1034-1042.	5.5	27
46	High resolution oligonucleotide CGH using DNA from archived prostate tissue. Prostate, 2007, 67, 1447-1455.	2.3	23
47	Identification of multiple CpG islands and associated conserved sequences in a candidate region for the Huntington disease gene. Genomics, 1991, 11, 1113-1124.	2.9	21
48	Genomic Profiling of Hormone-Na \tilde{A} -ve Lymph Node Metastases in Patients with Prostate Cancer. Neoplasia, 2006, 8, 1083-IN35.	5.3	21
49	Detection of recurrent rearrangement breakpoints from copy number data. BMC Bioinformatics, 2011, 12, 114.	2.6	21
50	Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4. Oncotarget, 2017, 8, 66878-66888.	1.8	21
51	Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer. European Urology, 2018, 73, 949-960.	1.9	19
52	RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression. European Urology, 2019, 76, 157-166.	1.9	19
53	Evolution of 8p loss in transformed human prostate epithelial cells. Cancer Genetics and Cytogenetics, 2004, 154, 36-43.	1.0	17
54	Computational BAC clone contig assembly for comprehensive genome analysis. Genes Chromosomes and Cancer, 2004, 40, 66-71.	2.8	15

#	Article	IF	CITATIONS
55	Construction and application of a full-coverage, high-resolution, human chromosome 8q genomic microarray for comparative genomic hybridization. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2005, 63A, 10-19.	1.5	15
56	Exclusion of DNA changes in the $\hat{l}^2\hat{a}\in$ "subunit of the câ \in "GMP phosphodiesterase gene as the cause for Huntington's disease. Nature Genetics, 1992, 1, 104-108.	21.4	12
57	Evaluation of Whole Genome Amplification Protocols for Array and Oligonucleotide CGH. Diagnostic Molecular Pathology, 2007, 16, 198-206.	2.1	11
58	Androgen receptor (AR) antagonism triggers acute succinateâ€mediated adaptive responses to reactivate AR signaling. EMBO Molecular Medicine, 2021, 13, e13427.	6.9	11
59	Quantification of large scale DNA organization for predicting prostate cancer recurrence. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2017, 91, 1164-1174.	1.5	10
60	Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications. Molecular Cancer Research, 2022, 20, 782-793.	3.4	10
61	Immune-focused multi-omics analysis of prostate cancer: leukocyte lg-Like receptors are associated with disease progression. Oncolmmunology, 2020, 9, 1851950.	4.6	8
62	Delineation of a 50 kilobase DNA segment containing the recombination site in a sporadic case of Huntington's disease. Nature Genetics, 1992, 2, 216-222.	21.4	7
63	ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development. Prostate Cancer and Prostatic Diseases, 2021, 24, 775-785.	3.9	0
64	Genome Scanning and Gene Discovery in Breast and Ovarian Cancer. , 1998, , 65-72.		0